Compare ASTL & ALT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ASTL | ALT |
|---|---|---|
| Founded | 1902 | 1997 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Steel/Iron Ore | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 481.8M | 573.8M |
| IPO Year | 2021 | 2005 |
| Metric | ASTL | ALT |
|---|---|---|
| Price | $4.14 | $3.08 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $17.67 |
| AVG Volume (30 Days) | 1.3M | ★ 4.2M |
| Earning Date | 05-07-2026 | 05-08-2026 |
| Dividend Yield | ★ 1.12% | N/A |
| EPS Growth | N/A | ★ 25.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $41,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $23.04 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 105.00 |
| 52 Week Low | $3.02 | $2.56 |
| 52 Week High | $5.90 | $6.44 |
| Indicator | ASTL | ALT |
|---|---|---|
| Relative Strength Index (RSI) | 47.81 | 51.70 |
| Support Level | $4.06 | $2.80 |
| Resistance Level | $4.60 | $3.09 |
| Average True Range (ATR) | 0.30 | 0.13 |
| MACD | -0.03 | 0.00 |
| Stochastic Oscillator | 19.40 | 57.32 |
Algoma Steel Group Inc is a fully integrated steel producer of hot and cold rolled steel products, including coiled sheet and plate, strategically located. The firm operates in a single segment of basic steel production including sheets, plates, slabs, and freights. The company's revenue is generated from contracts to produce, ship, and deliver steel products Geographically it serves Canada, the United States, and the rest of the world, whilst driving key revenue from United States. The company generates the majority of its revenue from the sale of Steel sheets and strips.
Altimmune Inc is a late clinical-stage biopharmaceutical company developing therapies for patients with serious liver diseases. The Company's key candidate, pemvidutide, is a dual-action therapy targeting both glucagon and GLP-1 receptors in a balanced 1:1 ratio in development for the treatment of metabolic dysfunction-associated steatohepatitis (MASH), alcohol use disorder (AUD), and alcohol-associated liver disease (ALD). The company also plans to pursue additional indications for pemvidutide that leverage the differentiated clinical profile of pemvidutide.